First Header Logo Second Header Logo

Connection

Samuel Lentz to Doxorubicin

Back to Details
This is a "connection" page, showing publications Samuel Lentz has written about Doxorubicin.
Samuel Lentz
Connection Strength
0.058
Doxorubicin
  1. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, Burger RA, Andersen W. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2003 Oct 15; 21(20):3808-13.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.